secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0000950170-23-017157
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q1 revenue $59M via Janssen termination; cuts workforce, runway to 2H25
--------------------------------------------------------------------------------

- Q1 GAAP operating expenses $87.6M including $12.9M severance; revenue includes $52.3M from Janssen termination.
- Cash, cash equivalents & investments $412.8M; with $13.5M receivables, expects >$300M at year-end 2023.
- Discontinued Janssen collaboration, withdrew IND; terminated NK programs FT516, FT596, FT538, FT536.
- Workforce reduced to ~220 employees; 2023 GAAP op-ex guidance $265M-$285M.
- FT576 enrolling multi-dose cohorts; FT522 IND submitted; FT819 advancing; HER2 IND planned 2H23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/0000950170-23-017157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/fate-20230503.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer